Navigation Links
Vanda Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference
Date:5/31/2013

WASHINGTON, May 31, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that it will deliver a corporate presentation at the Jefferies Global Healthcare Conference in New York City on Thursday, June 6, 2013 at 2:30 p.m. Eastern Time.

The presentation at the Jefferies Global Healthcare Conference will be available live on Vanda's corporate website, where it also will be archived for 30 days.  To access the presentation, go to Vanda's website at www.vandapharma.com and click on the Presentations tab on the Investor Relations page.  Please connect to the website several minutes prior to the start of the live presentation.

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.

Company Contact:
Jim Kelly
Senior Vice President and Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Vanda Announces Submission To FDA Of A New Drug Application For Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
2. Vanda to Present Tasimelteon Non-24 Phase III Data at Two Medical Meetings
3. Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland
4. Vanda Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 9, 2013
5. Vanda Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
6. Vanda Reports Successful Completion Of Pre-NDA Meeting With FDA On Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
7. Vanda Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference
8. Vanda Pharmaceuticals Reports Fourth Quarter 2012 and Full Year 2012 Results
9. Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint
10. Vanda Announces Positive Results in the Second Phase III Study (RESET) of Tasimelteon for the Treatment of Non-24-Hour Disorder
11. Vanda Pharmaceuticals to Announce Fourth Quarter 2012 Financial Results on February 12, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017 ... stimulate an immune response in pets such as ... products are of various types such as Attenuated ... Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated ... as virus or bacteria, which have been weakend ...
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
(Date:4/18/2017)... , April 18, 2017  Cardinal Health (NYSE: ... fiscal 2017 earnings per share (EPS) guidance and ... This is in conjunction with this morning,s announcement of ... Thrombosis and Nutritional Insufficiency businesses. Cardinal Health ... operations will be at the bottom of its previous ...
Breaking Medicine Technology:
(Date:4/25/2017)... , ... April 25, 2017 , ... Back Pain ... and back pain with a reputable physician in their area, announces the launch of ... patient information for patients who are looking for reputable physicians to help them with ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest quality ... problems, I focus on preventative care with all my patients to alleviate possible future issues. ... feel free to contact my office and my trained staff will assist you in any ...
(Date:4/25/2017)... ... ... Emergency Physician and Distinguished Professor of Emergency Medicine Bentley Bobrow will be featured ... publish in summer 2017. , Dr. Bobrow, MD, FACEP, FAHA, is an Emergency ... He also serves as Medical Director for the Bureau of Emergency Medical Services and ...
(Date:4/25/2017)... ... , ... Vetoquinol USA® , a world-class developer of ... the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin ... , The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and ...
(Date:4/24/2017)... Massachusetts (PRWEB) , ... April 24, 2017 , ... ... will help busy nursing professionals advance their careers. Beginning in the fall of 2017, ... Nursing (BSN) degree in as few as 16 months and for as little as ...
Breaking Medicine News(10 mins):